Daily close, T-120 (5/19/25) through T+5. Run-up high $43.45 on 10/21/25, low $28.03 on 5/20/25 (T-120 to T-1). FDA decision 11/3/25. Historical price action, not a forecast.
Positioning before the decision
On Oct 20, 2025, 14 days before the decision date, at-the-money options priced a move of ±17.1% through Nov 21, 2025 (the first listed expiry after the decision; ATM implied volatility 69%). The stock closed -7.2% at the first close across the decision and -5.9% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Kygevvi (doxecitine and doxribtimine) approved by the FDA?
Yes. The FDA approved the application for Kygevvi (doxecitine and doxribtimine) on November 3, 2025. The primary source is linked on this page.
What was Kygevvi (doxecitine and doxribtimine) under FDA review for?
The application covered Thymidine kinase 2 deficiency. The FDA approved the application on November 3, 2025.
How did AGIO stock react to the FDA decision?
On the decision day AGIO moved -7.2%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.